Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
STF-31
Cat. No.:
0225LY-0512
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
STF-31 targets and inhibits glucose transporter 1 (GLUT1), exhibiting an IC50 of 1 μM.
Synonym:
724741-75-7; STF 31; STF31; 4-[[(4-tert-Butylphenyl)sulfonylamino]methyl]-N-pyridin-3-ylbenzamide; 4-((4-(tert-Butyl)phenylsulfonamido)methyl)-N-(pyridin-3-yl)benzamide; 4-((((4-(1,1-Dimethylethyl)phenyl)sulfonyl)amino)methyl)-N-3-pyridinylbenzamide
CAS No.:
724741-75-7
Compound CID:
984333
Formula:
C23H25N3O3S
Formula Weight:
423.53
Specification
Targets&IC50:
GLUT1: 1 μM.
Relative Density:
1.247 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
STF-31 can be used in glucose metabolism studies to explore its role as a selective inhibitor of GLUT1 in cancer cells.
Library Information
Target:
Glucose transporter
Receptor:
GLUT1
Pathways:
Autophagy; Metabolism
Plate Number:
AOCL-7
Plate Location:
f4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
42.4 mg/mL; 100.11 mM
Ethanol Max Solubility:
25 mg/mL; 59.03 mM
ALogP:
3.359
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
7
